News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
515,059 Results
Type
Article (13119)
Company Profile (158)
Press Release (501687)
Multimedia
Podcasts (23)
Webinars (8)
Section
Business (174700)
Career Advice (521)
Deals (26994)
Drug Delivery (42)
Drug Development (56262)
Employer Resources (43)
FDA (10817)
Job Trends (9413)
News (251000)
Policy (19457)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (727)
Accelerated approval (30)
ADA (24)
Adcomms (8)
Allergies (108)
Alliances (35103)
ALS (109)
Alzheimer's disease (1052)
Antibody-drug conjugate (ADC) (303)
Approvals (11407)
Artificial intelligence (392)
ASCO (172)
Autoimmune disease (235)
Automation (37)
Bankruptcy (284)
Best Places to Work (7512)
BIO (43)
Biologics (2)
BIOSECURE Act (10)
Biosimilars (145)
BioSpace Insights (44)
Biotechnology (100)
Bladder cancer (142)
Brain cancer (34)
Breast cancer (542)
Cancer (3926)
Cardiovascular disease (297)
Career advice (447)
Career pathing (8)
CAR-T (191)
CDC (5)
Celiac Disease (1)
Cell therapy (541)
Cervical cancer (38)
Clinical research (50720)
Collaboration (1419)
Commercialization (4)
Company closure (4)
Compensation (1486)
Complete response letters (41)
COVID-19 (1012)
CRISPR (71)
C-suite (856)
Cystic fibrosis (90)
Data (6104)
Denatured (11)
Depression (119)
Dermatology (65)
Diabetes (411)
Diagnostics (4425)
Digital health (45)
Diversity (2)
Diversity, equity & inclusion (7)
Drug discovery (205)
Drug pricing (66)
Drug shortages (7)
Duchenne muscular dystrophy (193)
Earnings (75862)
Editorial (21)
Employer branding (4)
Employer resources (39)
Events (90937)
Executive appointments (780)
FDA (13664)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (1100)
Gene editing (149)
Generative AI (17)
Gene therapy (390)
GLP-1 (471)
Government (1350)
Grass and pollen (3)
Guidances (310)
Healthcare (10207)
Hematology (100)
HIV (57)
Huntington's disease (27)
IgA nephropathy (86)
Immunology and inflammation (150)
Immuno-oncology (71)
Indications (168)
Infectious disease (1236)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (93)
Intellectual property (269)
Interviews (96)
IPO (12862)
IRA (13)
Job creations (2244)
Job search strategy (375)
JPM (12)
Kidney cancer (20)
Labor market (26)
Layoffs (147)
Leadership (20)
Legal (5480)
Licensing (8)
Liver cancer (53)
Longevity (21)
Lung cancer (536)
Lymphoma (269)
Machine learning (33)
Management (20)
Manufacturing (659)
Marketing (9)
MASH (129)
Medical affairs (1)
Medical device (9344)
Medtech (9499)
Mergers & acquisitions (15205)
Metabolic disorders (908)
mRNA (81)
Multiple sclerosis (116)
NASH (4)
Neurodegenerative disease (245)
Neuropsychiatric disorders (54)
Neuroscience (2021)
NextGen: Class of 2026 (3533)
Non-profit (1139)
Now hiring (16)
Obesity (332)
Opinion (90)
Ovarian cancer (161)
Pain (185)
Pancreatic cancer (217)
Parkinson's disease (219)
Partnered (21)
Patents (513)
Patient recruitment (538)
Peanut (34)
People (43501)
Pharmaceutical (31)
Pharmacy benefit managers (13)
Phase 1 (16151)
Phase 2 (22503)
Phase 3 (15679)
Pipeline (7899)
Policy (87)
Postmarket research (1806)
Preclinical (6837)
Press Release (35)
Prostate cancer (201)
Psychedelics (18)
Radiopharmaceuticals (209)
Rare diseases (669)
Real estate (3372)
Recruiting (17)
Regulatory (16139)
Reports (31)
Research institute (788)
Resumes & cover letters (62)
Rett syndrome (43)
RNA editing (14)
RSV (56)
Schizophrenia (115)
Series A (195)
Series B (145)
Service/supplier (5)
Sickle cell disease (68)
Special edition (7)
Spinal muscular atrophy (92)
Sponsored (13)
Startups (2356)
Stomach cancer (5)
Supply chain (66)
Tariffs (21)
The Weekly (11)
Vaccines (413)
Venture capital (52)
Weight loss (179)
Women's health (86)
Worklife (1)
Date
Last 7 days (241)
Last 30 days (1653)
Last 365 days (20700)
2026 (13442)
2025 (20828)
2024 (24461)
2023 (28114)
2022 (36655)
2021 (39460)
2020 (35941)
2019 (25357)
2018 (19255)
2017 (20278)
2016 (19473)
2015 (25785)
2014 (22788)
2013 (19136)
2012 (21341)
2011 (21517)
2010 (21374)
Location
Africa (295)
Alabama (78)
Alaska (2)
Arizona (318)
Arkansas (11)
Asia (20556)
Australia (2599)
California (12468)
Canada (3226)
China (651)
Colorado (496)
Connecticut (426)
Delaware (239)
Europe (31541)
Florida (1849)
Georgia (392)
Hawaii (4)
Idaho (48)
Illinois (753)
India (65)
Indiana (361)
Iowa (15)
Japan (439)
Kansas (113)
Kentucky (31)
Louisiana (32)
Maine (26)
Maryland (1258)
Massachusetts (8243)
Michigan (320)
Minnesota (618)
Mississippi (5)
Missouri (91)
Montana (20)
Nebraska (11)
Nevada (127)
New Hampshire (65)
New Jersey (2812)
New Mexico (12)
New York (2889)
North Carolina (1376)
North Dakota (4)
Northern California (6287)
Ohio (300)
Oklahoma (18)
Oregon (23)
Pennsylvania (2312)
Puerto Rico (23)
Rhode Island (32)
South America (484)
South Carolina (77)
South Dakota (1)
Southern California (5113)
Tennessee (139)
Texas (2007)
United States (40695)
Utah (368)
Vermont (1)
Virginia (162)
Washington D.C. (44)
Washington State (1000)
West Virginia (2)
Wisconsin (87)
Wyoming (1)
515,059 Results for "pressure biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit its 2030 goal of $80 billion in revenue.
May 18, 2026
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
March 30, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
August 4, 2026
·
14 min read
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
July 27, 2026
·
2 min read
·
Tristan Manalac
Earnings
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
August 5, 2026
·
3 min read
·
Tristan Manalac
Regulatory
Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study
Sponsors of the pivotal study behind Amgen’s rare disease drug Tavneos saw unblinded findings for the drug and re-adjudicated data from nine patients to make the drug seem effective, according to European regulators.
August 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
BioLab Holdings Announces Publication of Real-World Evidence Study Evaluating Membrane Wrap™ for Pressure Ulcers
August 3, 2026
·
3 min read
Press Releases
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 6, 2026
·
10 min read
Regulatory
Amgen continues to defend Tavneos as global regulatory pressure mounts
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
July 10, 2026
·
4 min read
·
Nick Paul Taylor
Earnings
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
July 31, 2026
·
3 min read
·
Annalee Armstrong
1 of 51,506
Next
